OS Therapies Incorporated
OSTXAMEXHealthcare● Active
$1.79
+$0.01(+0.56%)
Market Cap$79723210
P/E Ratio—
52W High$2.57
52W Low$1.15
OS Therapies Incorporated (OSTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
OSTX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 18, 2026EPS Actual
-$0.27
Est. -$0.17 · -58.8%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 18, 2026
After Market Close
▼ Miss EPS
OSTX reports quarterly as a AMEX-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.20
Rev. $3.50B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.20
Rev. Est.$3.50B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 17, 2026 | -$0.17 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 18, 2026 | -$0.17 | -$0.27 | -58.8% | — | $0.00B | — |
| ▼ Q1 FY2026 | Mar 31, 2026 | -$0.14 | -$0.35 | -157.3% | — | — | — |
| ▼ Q4 FY2025 | Nov 14, 2025 | -$0.16 | -$0.21 | -31.3% | — | — | — |
| ▼ Q3 FY2025 | Aug 19, 2025 | -$0.15 | -$0.19 | -26.7% | — | — | — |
| ▼ Q2 FY2025 | May 15, 2025 | -$0.11 | -$0.18 | -63.6% | — | — | — |
| ▼ Q1 FY2025 | Mar 31, 2025 | -$0.14 | -$0.24 | -71.4% | — | — | — |
| ▼ Q4 FY2024 | Nov 15, 2024 | -$0.12 | -$0.18 | -50.0% | — | $0.00B | — |
Q3 FY2026
Aug 17, 2026
EPS Actual
—
EPS Est.
-$0.17
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 18, 2026Miss
EPS Actual
-$0.27
EPS Est.
-$0.17
EPS Surpr.
-58.8%
Revenue
—
Q1 FY2026
Mar 31, 2026Miss
EPS Actual
-$0.35
EPS Est.
-$0.14
EPS Surpr.
-157.3%
Revenue
—
Q4 FY2025
Nov 14, 2025Miss
EPS Actual
-$0.21
EPS Est.
-$0.16
EPS Surpr.
-31.3%
Revenue
—
Q3 FY2025
Aug 19, 2025Miss
EPS Actual
-$0.19
EPS Est.
-$0.15
EPS Surpr.
-26.7%
Revenue
—
Q2 FY2025
May 15, 2025Miss
EPS Actual
-$0.18
EPS Est.
-$0.11
EPS Surpr.
-63.6%
Revenue
—
Q1 FY2025
Mar 31, 2025Miss
EPS Actual
-$0.24
EPS Est.
-$0.14
EPS Surpr.
-71.4%
Revenue
—
Q4 FY2024
Nov 15, 2024Miss
EPS Actual
-$0.18
EPS Est.
-$0.12
EPS Surpr.
-50.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Q3 FY2028 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q2 FY2028 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Q1 FY2028 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Q4 FY2027 | $0.06 | $0.06 | $0.06 | 1 |
| Q3 FY2027 | $0.02 | $0.02 | $0.02 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 18, 2026 | -58.8% | $1.88 | $1.73 | -7.98% |
| ▼ Q1 FY2026 | Mar 31, 2026 | -157.3% | $1.33 | $1.41 | +6.02% |
| ▼ Q4 FY2025 | Nov 14, 2025 | -31.3% | $1.82 | $1.80 | -1.10% |
| ▼ Q3 FY2025 | Aug 19, 2025 | -26.7% | $2.18 | $2.15 | -1.38% |
| ▼ Q2 FY2025 | May 15, 2025 | -63.6% | $1.80 | $1.66 | -7.78% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -71.4% | $1.62 | $1.54 | -4.94% |
| ▼ Q4 FY2024 | Nov 15, 2024 | -50.0% | $2.20 | $2.20 | +0.00% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +0.0% | $3.20 | $3.16 | -1.25% |
Q2 FY2026-7.98%
Report Date
May 18, 2026
EPS Beat/Miss
-58.8%
Price Before
$1.88
Price After
$1.73
Q1 FY2026+6.02%
Report Date
Mar 31, 2026
EPS Beat/Miss
-157.3%
Price Before
$1.33
Price After
$1.41
Q4 FY2025-1.10%
Report Date
Nov 14, 2025
EPS Beat/Miss
-31.3%
Price Before
$1.82
Price After
$1.80
Q3 FY2025-1.38%
Report Date
Aug 19, 2025
EPS Beat/Miss
-26.7%
Price Before
$2.18
Price After
$2.15
Q2 FY2025-7.78%
Report Date
May 15, 2025
EPS Beat/Miss
-63.6%
Price Before
$1.80
Price After
$1.66
Q1 FY2025-4.94%
Report Date
Mar 31, 2025
EPS Beat/Miss
-71.4%
Price Before
$1.62
Price After
$1.54
Q4 FY2024+0.00%
Report Date
Nov 15, 2024
EPS Beat/Miss
-50.0%
Price Before
$2.20
Price After
$2.20
Q3 FY2024-1.25%
Report Date
Aug 14, 2024
EPS Beat/Miss
+0.0%
Price Before
$3.20
Price After
$3.16
Avg Beat Reaction-1.25%
Avg Miss Reaction-2.45%
Beat Rate1 / 8 quarters
Largest Move-7.98% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: OSTX ends December
OS Therapies Incorporated (OSTX) most recently reported earnings on May 18, 2026 for Q2 FY2026, posting EPS of $-0.27 — missing the analyst consensus of $-0.17 by -58.8%. The next OSTX earnings date is expected around September 1, 2026.
Each quarter, investors track OSTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. OSTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
OSTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
OSTX earnings · 5 questionsOS Therapies Incorporated's next earnings report is expected around September 1, 2026. OSTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; OSTX historically reports after market close (AMC).
OSTX earnings datewhen is OSTX earningsOSTX next earnings datewhen does OSTX report earningsOSTX earnings calendar
▸ Source: FMP · OS Therapies Incorporated SEC filings · US GAAP · OS Therapies Incorporated SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026